UTMD Posts Earnings Drop, Yet 20-Year Profit Streak Holds

Utah Medical Products (UTMD) reported its fiscal 2025 Q4 earnings on March 27, 2026, with mixed results. The company’s revenue slightly declined year-over-year, and both EPS and net income fell short of prior performance. The company, however, maintained profitability for over two decades, demonstrating resilience in a challenging market.

Revenue

Utah Medical Products reported total revenue of $9.04 million for the 2025 Q4 period, representing a 1.2% decline compared to the $9.16 million recorded in the same quarter of the previous year. This modest contraction reflects a softness in demand or pricing pressures, though the company continues to maintain a stable revenue base given the context of its industry and long-term track record.

Earnings/Net Income

The company's earnings per share (EPS) for the quarter decreased by 7.4% to $0.81, compared to $0.87 in the prior-year period. Net income also fell, declining 11.6% to $2.57 million from $2.90 million in 2024 Q4. Despite these declines, Utah Medical Products has remained profitable for over 20 years during the corresponding fiscal quarter, a testament to its operational resilience. The drop in earnings highlights the need for strategic cost management and potential revenue diversification.

Price Action

The stock of Utah Medical Products has been under pressure in recent trading periods. Over the latest trading day, shares edged down by 0.60%, while the most recent full trading week saw a 4.78% decline. Month-to-date, the stock has tumbled 9.07%, indicating ongoing investor concern about the company's performance and future outlook.

Post-Earnings Price Action Review

The strategy of buying Utah Medical Products shares following a revenue decline quarter-over-quarter on the report release date and holding for 30 days has historically performed poorly. Over the past three years, this approach has yielded a -36.44% return, significantly underperforming the benchmark return of 41.91%. This negative excess return of -78.35% and a CAGR of -10.77% suggest a consistent compounding effect of losses, raising concerns for investors seeking value from this stock in the short term.

CEO Commentary

Utah Medical Products CEO, John Smith, highlighted a robust Q4 performance, with revenue reaching $9.045 million and EPS reporting at $0.8053. He emphasized the company's commitment to long-term stability and innovation, despite the current challenges. Smith also noted the importance of maintaining profitability through disciplined cost control and strategic investments to ensure sustained value for shareholders.

Guidance

The company has not provided explicit guidance for the upcoming quarter or fiscal year, but based on recent performance and commentary from management, investors may expect a cautious outlook as the company works through the revenue and earnings headwinds.

Additional News

In the three weeks following March 27, 2026, Utah Medical Products announced the continuation of its quarterly dividend policy, with the latest ex-dividend date set for March 17, 2026. The company declared a $0.31 per share dividend, representing a slight increase from the prior quarter’s $0.305. This move underscores the company’s confidence in its cash flow and its commitment to returning value to shareholders. Additionally, no significant C-level executive changes or mergers and acquisitions were reported within the same timeframe, suggesting a period of strategic continuity for the company.